Health

Healthcare Economist Unbiased Analysis of Today’s Healthcare Issues

  • CMMI’s Advancing Chronic Care with Effective Scalable Solutions (ACCESS) Model Explained
    by Jason Shafrin on April 28, 2026 at 4:53 am

    In May 2025, CMS’s Center for Medicare & Medicaid Innovation (CMMI) unveiled it’s “Make America Healthy Again” vision. CMMI models focus on not only “protecting the federal taxpayer,” but also (i) promoting evidence-based prevention, (ii) empowering people to achieve their health goals, and (iii) driving choice and competition for people. CMMI has introduced a number…

  • 340B is a Hidden Tax Expenditure
    by Jason Shafrin on April 24, 2026 at 11:51 pm

    That is the argument made by Ike Brannon and Anthony Lo Sasso in a recent Health Affairs Forefront article. 340B allows hospitals serving low income communities to purchase pharmaceuticals at discounted rates, but then receive full price reimbursement from payers (e.g., commercial insurers, Medicare). It is not clear that the 340B program even benefits low-income…

  • Links
    by Jason Shafrin on April 24, 2026 at 4:37 am

    Simulate the risk AI displaces your job (methodology) LA’s “Great Stone Mother” Hospital. KFF CEO: What’s Wrong with U.S. Health Care CDC blocks publication of a study showing benefits of COVID vaccine Meta, AI and layoffs.

  • How are payers and providers using AI? And why isn’t AI reducing administrative cost?
    by Jason Shafrin on April 22, 2026 at 11:42 pm

    The Peterson Health Technology Institute (PHTI) recently released a report titled: “Administrative AI: Current Use and Potential Impact.” The report was based on a workshop PHTI convened with senior leaders from health systems, health plans, technology developers, investment firms, and federal agencies in order to discuss how technology and policy can enable AI to reduce…

  • What is the purpose of cost sharing for cell & gene therapies?
    by Jason Shafrin on April 21, 2026 at 12:03 am

    This is the question that a recent AJMCcommentary by William Shrank, Ellen Kelsay, and Mark Fendrick aims to answer. When talking about cell and gene therapies, the authors argue that cost sharing is not being used to avoid unnecessary use of low value care, but rather as a form of rationing that creates disparities in…